Calpains are ubiquitous, calcium-activated cysteine proteases involved in both physiological and pathological cellular functions. The two major forms, u-calpain (calpain I) and m-calpain (calpain II), are activated by micromolar and millimolar calcium concentrations, respectively.  A current and well-supported hypothesis is that cellular injury leads to elevated intracellular calcium and provokes the pathologic activation of calpains. Activation of calpains is believed to be responsible for the cell death and axonal degeneration seen in many acute and chronic neurological disorders, including stroke, spinal cord and head injuries, and peripheral neuropathies.  Calpain activation leads to degradation of the axonal cytoskeleton, and inhibition of calpains prevents axonal degeneration. Despite the importance of calpains in the pathogenesis of axonal degeneration in the central nervous system and peripheral nervous system, calpains have not been subjected to a systematic small-molecule screen.  We have developed a fluorescent enzyme activity assay in 1536-well format to identify small molecule inhibitors of calpain II, the isoform most likely to be involved in axonal degeneration.  This end-point assay measures the calpain II-dependent hydrolysis of a self-quenching fluorescent calpain II peptide substrate.  Fluorescence intensity (ex. 360 nm and em. 490 nm) is detected with an EnVision plate reader and is proportional to calpain II activity.  Assay Buffer (50mM HEPES pH 7.5, 10mM cysteine, 5mM CaCl2, 1mM DTT) Purified calpain II (Calbiochem cat # 208715) Fluorogenic calpain II peptide substrate (Calbiochem cat# 208771) Positive control calpain II inhibitor (AK295 peptide, provided by assay PI) 1. Add 4 ul Assay Buffer to all wells. 2. Transfer 0.1 ul of stock compounds to appropriate wells. 3. Add 1 ul of 1mM AK295 control compound to appropriate positive control wells. 4. Dispense 1 ul of ice cold calpain-2 (diluted 1:100 (42nM) in Assay Buffer). 5. Dispense 1 ul of Calpain Substrate III (reconstituted in 500 ul Assay Buffer (stock solution) then diluted 1:20 (15uM) in Assay Buffer). 6. Incubate reaction mixture for 30 minutes. 7. Read plate @ excitation of 360 nm and emission @ 490 nm. Data analysis - All data were normalized to plate controls using BioAssay software from CambridgeSoft.  PubChem Activity Score - Pct Inhibition was rounded to 0 decimal places.  Pct Inhibitions above 100 were set to 100, and those below 0 were set to 0. PubChem Activity Outcome - Compounds with >= 50% inhibition were marked as active, all others were marked as inactive.
bao:BAO_0001067 "1420" ; # "is primary assay of" -> "1420"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000222 ; # "has participant" -> "generic hydrolase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 "hydrolase activity assay" ; # "is bioassay type of" -> "hydrolase activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> bao:BAO_0000484 ; # "has assay design method" -> "enzyme inhibition"
bao:BAO_0000207 bao:BAO_0000363 ; # "has detection method" -> "fluorescence intensity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "To identify small molecule inhibitors of calpain II." ; # "screening campaign name" -> "To identify small molecule inhibitors of calpain II."
bao:BAO_0002853 "uHTS for Calpain Inhibitors" ; # "has assay title" -> "uHTS for Calpain Inhibitors"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "30 minute" ; # "substrate incubation time" -> "30 minute"
bao:BA0_0090012 bao:BAO_0000843 ; # "has participant" -> "AK295 peptide"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Jonathan Glass" ; # "material entity assay provider" -> "Jonathan Glass" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000693 ; # "has participant" -> "HEPES" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BAO_0002000 bao:BAO_0000843 ; # "has measured entity" -> "AK295 peptide" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35222> ; # "has role" -> "inhibitor"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 bao:BAO_0000888 ; # "has participant" -> "DABCYL-Thr-Pro-Leu-Lys~Ser-Pro-Pro-Pro-Ser-Pro-Arg-EDANS" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Calpain-2 catalytic subunit" ; # "has participant" -> "Calpain-2 catalytic subunit"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9823> ; # "has organism" -> "Sus scrofa"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P43367" ; # "uniprot ID" -> "P43367"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9823" ; # "NCBI taxonomy ID" -> "9823"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BA0_0090012 "DABCYL" ; # "has participant" -> "DABCYL"
bao:BA0_0090012 "EDANS" ; # "has participant" -> "EDANS"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "360 nanometer" ; # "has excitation wavelength value" -> "360 nanometer"
bao:BAO_0002918 "490 nanometer" ; # "has emission wavelength value" -> "490 nanometer"
bao:BAO_0000337 bao:BAO_0000201 ; # "has percent response" -> "percent inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "16" ; # "has concentration value" -> "16"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie" ; # "Annotated by" -> "kunie"
